Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch ...

H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

From STAT’s Matthew Herper: Eikon Therapeutics, the cell-biology-focused startup run by former Merck R&D head Roger ...

The company's flagship product, Rezdiffra, approved for the treatment of non-alcoholic steatohepatitis (NASH), has been the primary driver of its recent financial performance and future growth ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...